Monocyte activation in immunopathology: Cellular test for development of diagnostics and therapy

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Ivanova, Ekaterina A ^a   Orekhov, Alexander N ^b,c,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c Institute for Atherosclerosis Research   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN; CYTOKINE; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; APPARENT LIFE THREATENING EVENT; ATHEROSCLEROSIS; BREAST CANCER; CANCER SCREENING; CELL ACTIVATION; CYTOKINE RELEASE; DRUG RESEARCH; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; MACROPHAGE ACTIVATION; MONOCYTE; NEOPLASM; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANTIGEN PRESENTATION; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIGEN PRESENTATION; ATHEROSCLEROSIS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOPHENOTYPING; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES; NEOPLASMS;

EID: 84958568815     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/4789279     Document Type: Review

References (84)

1. F. Balkwill and A. Mantovani, "Inflammation and cancer: back to Virchow?" The Lancet, vol. 357, no. 9255, pp. 539-545, 2001.
2. S. K. Biswas and A. Mantovani, "Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, " Nature Immunology, vol. 11, no. 10, pp. 889-896, 2010.
3. M. Peled and E. A. Fisher, "Dynamic aspects of macrophage polarization during atherosclerosis progression and regression, " Frontiers in Immunology, vol. 5, no. 579, 2014.
4. J. E. Feig, S. Parathath, J. X. Rong et al. , "Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques, " Circulation, vol. 123, no. 9, pp. 989-998, 2011.
5. J. E. Feig, J. X. Rong, R. Shamir et al. , "HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7166-7171, 2011.
6. R. Ross, "Atherosclerosis-an inflammatory disease, " The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
7. C. Weber and H. Noels, "Atherosclerosis: current pathogenesis and therapeutic options, " Nature Medicine, vol. 17, no. 11, pp. 1410-1422, 2011.
8. G. K. Hansson and A. Hermansson, "The immune system in atherosclerosis, " Nature Immunology, vol. 12, no. 3, pp. 204-212, 2011.
9. R. Klingenberg and G. K. Hansson, "Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies, " European Heart Journal, vol. 30, no. 23, pp. 2838-2844, 2009.
10. R. Beaglehole and R. Bonita, "Global public health: a scorecard, " The Lancet, vol. 372, no. 9654, pp. 1988-1996, 2008.
11. J. F. Fries, "Strategies for reduction of morbidity, " The American Journal of Clinical Nutrition, vol. 55, supplement 6, pp. 1257S-1262S, 1992.
12. B. Mostert, A. M. Sieuwerts, J. Kraan et al. , "Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients, " Annals of Oncology, vol. 26, no. 3, pp. 510-516, 2015.
13. B. Mostert, A. M. Sieuwerts, J. Bolt-de Vries et al. , "mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients, "Molecular Oncology, vol. 9, no. 4, pp. 920-932, 2015.
14. V. Hofman, M. Ilie, E. Long et al. , "Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls, " Current Molecular Medicine, vol. 14, no. 4, pp. 440-456, 2014.
15. B. Polzer, G. Medoro, S. Pasch et al. , "Molecular profiling of single circulating tumor cells with diagnostic intention, " EMBO Molecular Medicine, vol. 6, no. 11, pp. 1371-1386, 2005.
16. B. Reynes, R. Diaz-Rua, M. Cifre, P. Oliver, and A. Palou, "Peripheral blood mononuclear cells as a potential source of biomarkers to test the efficacy ofweight-loss strategies, " Obesity, vol. 23, no. 1, pp. 28-31, 2015.
17. K. L. Bentley-Hewitt, R. K.-Y. Chen, R. E. Lill et al. , "Consumption of selenium-enriched broccoli increases cytokine production in human peripheral blood mononuclear cells stimulated ex vivo, a preliminary human intervention study, " Molecular Nutrition & Food Research, vol. 58, no. 12, pp. 2350-2357, 2014.
18. V. Bordignon, F. Palamara, G. Altomonte et al. , "A laboratory test based on determination of cytokine profiles: a promising assay to identify exposition to contact allergens and predict the clinical outcome in occupational allergic contact dermatitis, " BMC Immunology, vol. 16, article 4, 2015.
19. M. M. Venkataswamy, S. N. Madhusudana, S. S. Sanyal et al. , "Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes, " Clinical and Experimental Vaccine Research, vol. 4, no. 1, pp. 68-74, 2015.
20. M. G. Cardenas-Mondragon, G. Vallejo-Flores, J. Delgado-Dominguez et al. , "Preeclampsia is associated with lower production of vascular endothelial growth factor by peripheral blood mononuclear cells, " Archives of Medical Research, vol. 45, no. 7, pp. 561-569, 2014.
21. M. Jenny, M. Klieber, D. Zaknun et al. , "In vitro testing for antiinflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors, " Inflammation Research, vol. 60, no. 2, pp. 127-135, 2011.
22. A. N. Orekhov, I. A. Sobenin, M. A. Gavrilin et al. , "Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy, " Current Pharmaceutical Design, vol. 21, no. 9, pp. 1172-1179, 2015.
23. W. E. Hellings, W. Peeters, F. L. Moll, and G. Pasterkamp, "From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization, " Trends in Cardiovascular Medicine, vol. 17, no. 5, pp. 162-171, 2007.
24. J. A. Schaar, J. E. Muller, E. Falk et al. , "Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece, " European Heart Journal, vol. 25, no. 12, pp. 1077-1082, 2004.
25. N. V. Serbina, T. Jia, T. M. Hohl, and E. G. Pamer, "Monocytemediated defense against microbial pathogens, " Annual Review of Immunology, vol. 26, pp. 421-452, 2008.
26. R. van Furth and Z. A. Cohn, "The origin and kinetics of mononuclear phagocytes, " The Journal of Experimental Medicine, vol. 128, no. 3, pp. 415-435, 1968.
27. M. H. Sieweke and J. E. Allen, "Beyond stem cells: self-renewal of differentiated macrophages, " Science, vol. 342, no. 6161, Article ID 1242974, 2013.
28. N. P. Hurst and G. Nuki, "Evidence for defect of complementmediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis, " British Medical Journal, vol. 282, no. 6282, pp. 2081-2083, 1981.
29. G. Meuret and G. Hoffmann, "Monocyte kinetic studies in normal and disease states, " British Journal of Haematology, vol. 24, no. 3, pp. 275-285, 1973.
30. G. Meuret, J. Bammert, and G. Hoffmann, "Kinetics of human monocytopoiesis, " Blood, vol. 44, no. 6, pp. 801-816, 1974.
31. P. R. Taylor and S. Gordon, "Monocyte heterogeneity and innate immunity, " Immunity, vol. 19, no. 1, pp. 2-4, 2003.
32. F. Geissmann, S. Gordon, D. A. Hume, A. M. Mowat, and G. J. Randolph, "Unravelling mononuclear phagocyte heterogeneity, " Nature Reviews Immunology, vol. 10, no. 6, pp. 453-460, 2010.
33. S. J. Jenkins and D. A. Hume, "Homeostasis in the mononuclear phagocyte system, " Trends in Immunology, vol. 35, no. 8, pp. 358-367, 2014.
34. A. Bartocci, D. S. Mastrogiannis, G. Migliorati, R. J. Stockert, A. W. Wolkoff, and E. R. Stanley, "Macrophages specifically regulate the concentration of their own growth factor in the circulation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 17, pp. 6179-6183, 1987.
35. J. C. Gasson, "Molecular physiology of granulocyte-macrophage colony-stimulating factor, " Blood, vol. 77, no. 6, pp. 1131-1145, 1991.
36. P. J. Murray, J. E. Allen, S. K. Biswas et al. , "Macrophage activation and polarization: nomenclature and experimental guidelines, " Immunity, vol. 41, no. 1, pp. 14-20, 2014.
37. S. Gordon and F. O. Martinez, "Alternative activation of macrophages: mechanism and functions, " Immunity, vol. 32, no. 5, pp. 593-604, 2010.
38. C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, "M-1/M-2 macrophages and the Th1/Th2 paradigm, " The Journal of Immunology, vol. 164, no. 12, pp. 6166-6173, 2000.
39. S. Gordon and P. R. Taylor, "Monocyte and macrophage heterogeneity, " Nature Reviews Immunology, vol. 5, no. 12, pp. 953-964, 2005.
40. A. Gratchev, K. Schledzewski, P. Guillot, and S. Goerdt, "Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing, " Skin Pharmacology and Applied Skin Physiology, vol. 14, no. 5, pp. 272-279, 2001.
41. S. Gordon, "The macrophage, " BioEssays, vol. 17, no. 11, pp. 977-986, 1995.
42. F. De Paoli, B. Staels, and G. Chinetti-Gbaguidi, "Macrophage phenotypes and their modulation in atherosclerosis, " Circulation Journal, vol. 78, no. 8, pp. 1775-1781, 2014.
43. R. N. Hanna, I. Shaked, H. G. Hubbeling et al. , "NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis, " Circulation Research, vol. 110, no. 3, pp. 416-427, 2012.
44. M. J. Davies, "Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995, " Circulation, vol. 94, no. 8, pp. 2013-2020, 1996.
45. H. C. Stary, A. B. Chandler, R. E. Dinsmore et al. , "A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association, " Circulation, vol. 92, no. 5, pp. 1355-1374, 1995.
46. J. Rojas, J. Salazar, M. S. Martinez et al. , "Macrophage heterogeneity and plasticity: impact of macrophage biomarkers on atherosclerosis, " Scientifica, vol. 2015, Article ID 851252, 17 pages, 2015.
47. T. J. Koh and L. A. DiPietro, "Inflammation and wound healing: the role of the macrophage, " Expert Reviews in Molecular Medicine, vol. 13, article e23, 2011.
48. B. D. Fleming and D. M. Mosser, "Regulatory macrophages: setting the threshold for therapy, " European Journal of Immunology, vol. 41, no. 9, pp. 2498-2502, 2011.
49. A. Gratchev, J. Kzhyshkowska, K. Duperrier, J. Utikal, F. W. Velten, and S. Goerdt, "The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells, " Scandinavian Journal of Immunology, vol. 60, no. 3, pp. 233-237, 2004.
50. V. Kodelja, C. Muller, O. Politz, N. Hakij, C. E. Orfanos, and S. Goerdt, "Alternative macrophage activation-associated CCchemokine-1, a novel structural homologue of macrophage inflammatory protein-1α with a Th2-associated expression pattern, "The Journal of Immunology, vol. 160, no. 3, pp. 1411-1418, 1998.
51. O. Politz, A. Gratchev, P. A. G. McCourt et al. , "Stabilin-1 and - constitute a novel family of fasciclin-like hyaluronan receptor homologues, " The Biochemical Journal, vol. 362, no. 1, pp. 155-164, 2002.
52. M. M. Tiemessen, A. L. Jagger, H. G. Evans, M. J. C. van Herwijnen, S. John, and L. S. Taams, "CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19446-19451, 2007.
53. F. Martinon, K. Burns, and J. Tschopp, "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β, " Molecular Cell, vol. 10, no. 2, pp. 417-426, 2002.
54. K. J. Moore and I. Tabas, "Macrophages in the pathogenesis of atherosclerosis, " Cell, vol. 145, no. 3, pp. 341-355, 2011.
55. A. Sarkar, S. Mitra, S. Mehta, R. Raices, and M. D. Wewers, "Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1, " PLoS ONE, vol. 4, no. 9, Article ID e7140, 2009.
56. M. A. Gavrilin, S. Mitra, S. Seshadri et al. , "Pyrin critical to macrophage IL-1β response to Francisella challenge, " The Journal of Immunology, vol. 182, no. 12, pp. 7982-7989, 2009.
57. M. A. Gavrilin, D. H. A. Abdelaziz, M. Mostafa et al. , "Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia, " Journal of Immunology, vol. 188, no. 7, pp. 3469-3477, 2012.
58. F. Martinon, A. Mayor, and J. Tschopp, "The inflammasomes: guardians of the body, " Annual Review of Immunology, vol. 27, pp. 229-265, 2009.
59. C. A. Janeway Jr. and R. Medzhitov, "Innate immune recognition, " Annual Review of Immunology, vol. 20, pp. 197-216, 2002.
60. P. Duewell, H. Kono, K. J. Rayner et al. , "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, " Nature, vol. 464, no. 7293, pp. 1357-1361, 2010.
61. V. V. Valtonen, " Infection as a risk factor for infarction and atherosclerosis, " Annals of Medicine, vol. 23 no. 5 539-543 1991.
62. A. Luque, M. M. Turu, N. Rovira, J. O. Juan-Babot, M. Slevin, and J. Krupinski, "Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae, " Frontiers in Bioscience, vol. 4, no. 7, pp. 2423-2432, 2012.
63. M. Charakida and D. Tousoulis, "Infections and atheromatous plaque: current therapeutic implications, " Current Pharmaceutical Design, vol. 19, no. 9, pp. 1638-1650, 2013.
64. E. Krishnan, "Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout, " Rheumatology, vol. 49, no. 7, Article ID keq037, pp. 1229-1238, 2010.
65. B. Razani, C. Feng, T. Coleman et al. , "Autophagy links inflammasomes to atherosclerotic progression, " Cell Metabolism, vol. 15, no. 4, pp. 534-544, 2012.
66. E. F. Strasser and R. Eckstein, "Optimization of leukocyte collection and monocyte isolation for dendritic cell culture, " Transfusion Medicine Reviews, vol. 24, no. 2, pp. 130-139, 2010.
67. S. B. Clarkson and P. A. Ory, "CD16. Developmentally regulated IgG Fc receptors on cultured humanmonocytes, " The Journal of Experimental Medicine, vol. 167, no. 2, pp. 408-420, 1988.
68. S. Krause, A. Pohl, C. Pohl et al. , "Ex vivo investigation of blood monocyte and platelet behaviour in pigs maintained on an atherogenic diet, " Experimental and Toxicologic Pathology, vol. 44, no. 3, pp. 144-146, 1992.
69. F. P. Bell and R. G. Gerrity, "Evidence for an altered lipid metabolic state in circulating blood monocytes under conditions of hyperlipemia in swine and its implications in arterial lipid metabolism, " Arteriosclerosis and Thrombosis, vol. 12, no. 2, pp. 155-162, 1992.
70. A. Gratchev, P. Guillot, N. Hakiy et al. , "Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein βIG-H3, " Scandinavian Journal of Immunology, vol. 53, no. 4, pp. 386-392, 2001.
71. A. Gratchev, J. Kzhyshkowska, K. Kothe et al. , "Mβ1 and Mβ2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals, " Immunobiology, vol. 211, no. 6-8, pp. 473-486, 2006.
72. D. M. Mosser and J. P. Edwards, "Exploring the full spectrum of macrophage activation, " Nature Reviews Immunology, vol. 8, no. 12, pp. 958-969, 2008.
73. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al. , "CSF-1R inhibition alters macrophage polarization and blocks glioma progression, " Nature Medicine, vol. 19, no. 10, pp. 1264-1272, 2013.
74. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, "Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro, " Atherosclerosis, vol. 135, no. 1, pp. 19-27, 1997.
75. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, "Collagensynthesizing cells in initial and advanced atherosclerotic lesions of human aorta, " Atherosclerosis, vol. 130, no. 1-2, pp. 133-142, 1997.
76. E. J. Mills, B. Rachlis, P. Wu, P. J. Devereaux, P. Arora, and D. Perri, "Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65, 000 patients, " Journal of the American College of Cardiology, vol. 52, no. 22, pp. 1769-1781, 2008.
77. S. Hirayama and T. Miida, "Small dense LDL: an emerging risk factor for cardiovascular disease, " Clinica ChimicaActa, vol. 414, pp. 215-224, 2012.
78. D. Steinberg, S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum, "Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, " The New England Journal of Medicine, vol. 320, no. 14, pp. 915-924, 1989.
79. A. N. Orekhov, V. V. Tertov, and D. N. Mukhin, "Desialylated low density lipoprotein-naturally occurring modified lipoprotein with atherogenic potency, " Atherosclerosis, vol. 86, no. 2-3, pp. 153-161, 1991.
80. A. N. Orekhov, V. V. Tertov, A. E. Kabakov, I. Y. Adamova, S. N. Pokrovsky, and V. N. Smirnov, "Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foamcell formation, " Arteriosclerosis and Thrombosis, vol. 11, no. 2, pp. 316-326, 1991.
81. E. I. Chazov, A. N. Orekhov, N. V. Perova et al. , "Atherogenicity of blood serum from patients with coronary heart disease, " The Lancet, vol. 328, no. 8507, pp. 595-598, 1986.
82. A. N. Orekhov, V. V. Tertov, K. A. Khashimov, S. S. Kudryashov, and V. N. Smirnov, "Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells, " The American Journal of Cardiology, vol. 59, no. 5, pp. 495-496, 1987.
83. S. E. Akopov, A. N. Orekhov, V. V. Tertov, K. A. Khashimov, E. S. Gabrielyan, and V. N. Smirnov, "Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta The effect of calcium antagonists, " Atherosclerosis, vol. 72, no. 2-3, pp. 245-248, 1988.
84. A. N. Orekhov, V. V. Tertov, S. A. Kudryashov, K. A. Khashimov, and V. N. Smirnov, "Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents, "Atherosclerosis, vol. 60, no. 2, pp. 101-110, 1986.